A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy. Issue 13 (24th March 2023)

• Record Type: Journal Article
• Authors: Moore, Kristine A.; Leighton, Tabitha; Ostrowsky, Julia T.; Anderson, Cory J.; Danila, Richard N.; Ulrich, Angela K.; Lackritz, Eve M.; Mehr, Angela J.; Baric, Ralph S.; Baylor, Norman W.; Gellin, Bruce G.; Gordon, Jennifer L.; Krammer, Florian; Perlman, Stanley; Rees, Helen V.; Saville, Melanie; Weller, Charlotte L.; Osterholm, Michael T.
• Is Part Of: Vaccine. Volume 41:Issue 13(2023)
• Page Start: 2101
• Page End: 2112
• Publication Date: 2023-03-24
• Subjects: Coronavirus -- Pandemic preparedness -- COVID-19 vaccines -- Coronavirus vaccines -- Broadly protective coronavirus vaccines -- Roadmap -- Vaccine research; CEPI Coalition for Epidemic Preparedness Innovations -- CIDRAP Center for Infectious Disease Research and Policy -- CHIM controlled human infection model -- CoP Correlate of protection -- C-TAP COVID-19 Technology Access Pool -- CVR Coronavirus Vaccines Research and Development Roadmap -- DPP4 dipeptidyl peptidase 4 -- DNA deoxyribonucleic acid -- Fc-R Fc receptor -- FVVA full value of vaccine assessment -- GISRS Global Influenza Surveillance and Response System -- hACE2 human angiotensin converting enzyme-2 -- HICs high-income countries -- LMICs low- and middle-income countries -- MERS-CoV Middle East respiratory syndrome coronavirus -- PPC preferred product characteristics -- RBD receptor-binding domain -- R&D Research and Development -- RNA ribonucleic acid -- SARS-CoV severe acute respiratory syndrome coronavirus -- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 -- TPP target product profile -- US FDA US Food and Drug Administration -- WHO World Health Organization; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2023.02.032
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is aimed at promoting the development of such vaccines. The CVR, funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, was generated through a collaborative and iterative process, which was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and involved 50 international subject matter experts and recognized leaders in the field. This report summarizes the major issues and areas of research outlined in the CVR and identifies high-priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research campaigns that promote the development of broadly protective coronavirus vaccines.